Results 91 to 100 of about 4,926 (176)

Relationship of subclinical lung injury to chronic airway inflammation in spinocerebellar ataxia type 3. [PDF]

Orphanet J Rare Dis
Lv XT, Lin W, Ye BN, Zhang ZW, Lin H, Zhang JY, Zhou ZY, Cui ML, Huang ZY, Wang N, Gan SR, OSCCAR Investigators.   +11 more
europepmc   +1 more source

Hypothalamic Atrophy and Textural Changes in Polyglutamine Ataxias. [PDF]

Cerebellum
Rodrigues L, Rezende TJR, Martinez ARM, Massuyama B, Pedroso JL, Barsottini OGP, Iglesias JE, Appenzeller S, Rittner L, França MC.   +9 more
europepmc   +1 more source

Pediatric-onset spinocerebellar ataxia type 3 with dual <i>ATXN3</i> and <i>HTT</i> gene mutations: a case report and literature-informed hypothesis. [PDF]

Front Genet
Wang D, Zhou M, Du K, Wang Y, Tang K, Duan Y, Shi M, Wu H.   +7 more
europepmc   +1 more source

IGFBP1 as a metabolic-neurodegenerative biomarker in spinocerebellar ataxia type 3. [PDF]

Exp Ther Med
Chiu C, Cheng W, Lin T, Chang H, Chang Y, Su S, Lee C, Chang H, Liu C.   +8 more
europepmc   +1 more source

Repurposing of natural products for spinocerebellar ataxia type 3 using integrated network pharmacology and in silico approaches. [PDF]

Sci Rep
Roney M, Mohd Hisam NS, Uddin MN, Istiaque Hamim SM, Lim LW, Wong KH.   +5 more
europepmc   +1 more source

Gastrodin inhibits the formation of ataxin-3 aggregates by regulating the level of ERK1/2/P38 proteins. [PDF]

Orphanet J Rare Dis
Wang Z, Xiao X, Wang M, Cheng R, Wang C, Liu Y, He F, Xie X.   +7 more
europepmc   +1 more source

SCA3 Can Manifest Phenotypically with ALS-like Characteristics

Internal Medicine
Zarrouk, Sinda, Finsterer, Josef
openaire   +2 more sources

Peripheral and autonomic nervous system involvement in spinocerebellar ataxia type 3: unveiling an invisible burden. [PDF]

J Neurol
Leeuwenberg KE, van Alfen N, van de Warrenburg BP, Maas RPPWM.   +3 more
europepmc   +1 more source

Extracellular vesicles-mediated delivery of SpCas9 RNPs for therapeutic gene editing in Spinocerebellar Ataxia Type 3. [PDF]

Biomaterials
Leandro K, Rufino-Ramos D, Lopes SM, Silva FS, Rodrigues-Santos P, Silva AC, Fernandes AR, Henriques C, Pereira D, Lobo D, Gabriel GL, Faro R, Nobre RJ, Perdigão PRL, Kleinstiver BP, de Almeida LP.   +15 more
europepmc   +1 more source

Selective silencing of expanded CAG repeats: Chemically modified siRNA advances RNA-based therapies for polyglutamine diseases. [PDF]

Mol Ther Nucleic Acids
Scholten GJ, Hyde JT, Buijsen RAM.
europepmc   +1 more source